Best-effort research profile: this record has not passed full two-source scientific verification. Descriptive fields, research protocols, storage/handling notes, and interaction guidance below are shown with their evidence labels, but calculator presets and exact dosing math remain hidden until the record is verified or reaches Community-Supported status.
Quick Facts
Reference Sizes
1 g, 5 g
Storage
No approved consumer storage standard exists for this presentation; follow the lot-specific COA and validated stability data
Solubility
Slightly better water-solubility than resveratrol; fat-soluble; take with food
Best-Effort Research Profile
Pterostilbene is a naturally occurring dimethylated analog of resveratrol, with two methoxy groups conferring substantially improved oral bioavailability and metabolic stability versus resveratrol itself. It is studied for similar proposed mechanisms (sirtuin pathway modulation, antioxidant activity), positioned in the geroscience literature as one of the 'natural analogs' that may perform more consistently than resveratrol in human contexts.
Source review pending. This descriptive profile is shown from the available source material as a best-effort educational reference. It has not passed the full verification bar and is not a dosing instruction, medical claim, or treatment recommendation.
Research Profile
Half-Life
Longer than resveratrol due to reduced first-pass metabolism (methylation resists glucuronidation)
Onset
Metabolic/antioxidant outcome studies typically run weeks to months
Administration Routes (Research)
Oral
Reported Research Effects
Improved oral bioavailability vs. resveratrol
Proposed sirtuin-pathway modulation and antioxidant activity
Reported Research Side Effects
Human safety, pharmacokinetics, and interaction data are incomplete
Data source: Primary literature, regulator records, trial registries, and identity-specific evidence search
Reflects preclinical/research literature context only. Not a medical claim, dosing instruction, or treatment recommendation.
Route-Specific Research Protocols
Amounts and schedules are separated by administration route. Evidence badges distinguish labels, human studies, preclinical work, community reports, and evidence gaps.
Label / guidelineHuman studyCommunity onlyPreclinical onlyNot established
OralHuman study only
125 mg twice daily in a randomized lipid and blood-pressure trial
Frequency / timing
Twice daily
Duration / setting
6-8 weeks
Technique
Oral
Evidence
Human study protocol
Context: clinical trial evidence
Formulation: Oral-mucosal formulations are not dose-equivalent to injectable or topical formulations.
Route safety: Research-study protocol only; it is not an approved or individualized instruction and should not be extrapolated to another route.
Do not convert an amount between routes. Bioavailability, formulation, sterility, monitoring, and clinical context differ by route. Research-use context only; independently verify every cited source.
Research Notes
The trial reported LDL-cholesterol increases in some groups; broad anti-aging claims are not established.
Supplementary research context only. Not medical advice or a treatment recommendation.
Found a relevant Reddit or forum thread about this compound? Suggest it below. Every suggestion is reviewed by an editor before it appears -- nothing is published automatically.
Related Research Articles
Published articles on this site that mention Pterostilbene or one of its catalog aliases.
Research Use Only. All content is for educational and research reference only. Not medical advice, a treatment recommendation, or guidance on human use. Compounds are not FDA-approved drugs unless specifically noted.